HEALTH: Summary of Oct 22, 2026

By · Published on

Illustration of glass medicine vials
AI-generated illustration; does not depict the actual event.

The Ebola outbreak that began in Congo has now reached Nigeria, while Kenya has confirmed another case. Researchers presented a tool that reads health risks from a face, a large UK dementia trial has begun recruiting, and Britain has withdrawn a travel vaccine. A long-running study also found no overall link between ultra-processed food and bowel cancer.

Nigeria’s Ebola case matches the Congo strain as Kenya confirms a ninth infection

Nigerian officials said their first case in the current outbreak is the Bundibugyo strain driving the epidemic in the Democratic Republic of Congo, which has killed 4,381 people from more than 9,000 confirmed cases since mid-May. The patient, a diplomat who travelled from Uganda to Abuja on 3 October, has suffered multiple organ failure, and 44 contacts are being monitored. Nigeria is the fourth African country affected, and the Africa CDC has called a ministerial meeting for next Wednesday.

In Kenya, health authorities confirmed a ninth case, a 24-year-old man who was already in quarantine as a close contact of the index patient, who caught the virus in Congo and died in Nairobi on 5 October. Officials say all cases belong to one cluster and that 134 of 135 identified contacts have been traced and quarantined. Campaigners have warned that many people are treating the outbreak casually, although there is no approved vaccine for this strain.

Bundibugyo virus is one of the viruses that cause Ebola disease in humans, a form of viral haemorrhagic fever. It takes its name from a district in western Uganda where it was first identified and was described in 2008. It caused outbreaks in 2007 and 2012, and the 2026 epidemic is the fastest-growing Ebola outbreak on record. The species was renamed Orthoebolavirus bundibugyoense in 2023 under current virus naming rules.


Facial photo tool estimates biological age and cancer survival

Researchers at Mass General Brigham in Massachusetts have built a tool that predicts a cancer patient’s chances of survival from one photograph of the face, in a study published in Lancet Digital Health. Trained on more than 40 million facial images, the system powers two models: one estimates biological age, and the other predicts survival directly. Among radiotherapy patients, those who appeared at least five years older than their real age had a 21 per cent higher risk of death during follow-up.

People who looked five or more years younger had a 17 per cent lower risk. The two models focus on different areas of the face, such as the lines from nose to mouth, the temples and the area beneath the eyes. Heavy drinking, drug use and smoking were linked with looking older. The team said the tool could help doctors judge frailty before intensive treatment, not replace their judgement, and that more research is needed before wider use.

Biomarkers of ageing are measures intended to predict a person’s later functional capacity better than their age in years, giving what scientists call biological age. Greying hair and wrinkled skin rise with age, but how well such changes in appearance forecast future health compared with chronological age has not been firmly established. Researchers have also developed so-called ageing clocks based on large datasets, including epigenetic and blood-based measures.


UK trial will test diabetes and ADHD drugs on people with Alzheimer’s

A UK study called AD-SMART has begun recruiting 1,200 people with Alzheimer’s disease to test whether two existing medicines can be repurposed. Participants will receive a placebo, the ADHD drug atomoxetine or the diabetes drug metformin. Because the trial can test several drugs at once and add new ones later, its organisers say it could halve the time needed to evaluate promising treatments. It is led by the UK Dementia Research Institute and Alzheimer’s Research UK, with £4.2m of public funding.

Atomoxetine acts on noradrenaline, a brain chemical involved in attention and memory, and earlier research suggests people with diabetes who take metformin have a lower risk of dementia. The chief investigator, Professor Paresh Malhotra of Imperial College London, said only about 200 people joined UK Alzheimer’s trials last year. The trial will include a broader group of patients than many studies. First interim results are expected in about two and a half years, with full results in late 2030.

Lecanemab, an antibody that targets amyloid beta in the brain, is one of the newer Alzheimer’s drugs the study’s organisers mentioned, and it was turned down for NHS use on cost grounds. It is approved only for mild cognitive impairment or mild dementia. A 2026 review found no effect or at best a small effect, and it can cause swelling or small bleeds in the brain, which are often without symptoms but occasionally serious.


UK withdraws the Ixchiq chikungunya vaccine after a safety review

Britain’s medicines regulator has withdrawn the UK licence for Ixchiq, a live chikungunya vaccine, after concluding that its benefits no longer outweigh its risks. Health professionals have been told to stop prescribing, supplying or giving it and to dispose of remaining stock. Serious reactions mainly affected older adults and people with underlying conditions, but some occurred in otherwise healthy people, and some led to hospital admission or death. The vaccine was approved in the UK in February 2025.

In February this year the regulator had already barred its use in adults over 60 and in people with high blood pressure, heart disease, diabetes or chronic kidney disease. Travellers to affected regions are advised to consider an alternative vaccine and to avoid mosquito bites. People who received Ixchiq without side effects need take no action, while anyone with a suspected reaction should seek medical advice and report it through the Yellow Card scheme.

Chikungunya is a virus spread mainly by Aedes mosquitoes that bite in the daytime, and it is found in warm regions of the Americas, Africa, Asia and the Pacific. It can cause fever with severe joint pain, sometimes lasting months, and there is no specific antiviral treatment. A second vaccine, Vimkunya, which uses virus-like particles, was authorised in the European Union in February 2025, while European regulators restricted Ixchiq to high-risk people in June 2026.


Large US study finds no overall link between ultra-processed food and bowel cancer

A study of more than 460,000 American adults found no association between total consumption of ultra-processed food and the incidence of colorectal cancer, according to results published on 15 October in PLOS Medicine. Researchers led by Erikka Loftfield of the US National Cancer Institute used data from people aged 50 to 71 who joined a long-running diet and health study in 1995 and 1996, following them for a median of almost 19 years.

The picture changed when foods were split into groups. Whole grains, fibre, dairy and calcium from ultra-processed sources were linked with lower incidence, while processed meat was linked with higher incidence, and swapping a tenth of such food by weight for minimally processed food was tied to a two per cent lower rate. The authors cautioned that participants were mostly older and white, and that diet was measured only once at the start.

Ultra-processed foods are industrially made products, often containing additives such as preservatives, emulsifiers and flavourings, and the term is usually linked to the Nova classification devised by Brazilian researchers in 2009. They make up 58 per cent of daily calories in the United States and 57 per cent in the United Kingdom. Observational studies have tied them to obesity and some cancers, but critics say the category is loosely defined and causes remain unproven.

In this topic